Nasdaq gnlx.
In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.
GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...WebGenelux Co. (NASDAQ:GNLX – Free Report) – Equities researchers at HC Wainwright issued their FY2023 EPS estimates for Genelux in a research report issued …WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...
NASDAQ GNLX opened at $11.10 on Monday. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.Nov 30, 2023 · 4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ... Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.
29. 3. 2023 ... Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation ...Mar 23, 2023 · WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...
4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebNov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...
WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...Web
WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...
WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Genelux IPO prices at bottom of range. Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha... 11 months ago - Market Watch.Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...Jul 20, 2023 · WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ... Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.
Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.On September 18, 2023, John Thomas, a director at Genelux Corp ( NASDAQ:GNLX ), sold 6,667 shares of the company. This move comes amidst a year where the insider has sold a total of 6,667 shares ...Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...Genelux Corporation (GNLX) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » GNLX Genelux …
In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.Web
About After Hours Quotes. Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. $202.77 1.43%. Bed Bath & Beyond Inc. Common Stock. Genelux Corporation (NASDAQ:GNLX) declined 8.7% to $10.83. Tharimmune, Inc. (NASDAQ:THAR) shares fell 8.6% to $0.1922. Tharimmune shares climbed around 17% on Friday after the company announced a ...On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts.Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ...If you're new to stock investing, here's how to buy Genelux stock. What is the 52 week high and low for Genelux (NASDAQ: GNLX)? (NASDAQ: GNLX) Genelux's 52-week high was $40.98, and its 52-week low was $5.35. It is currently -57.93% from its 52-week high and 222.24% from its 52-week low.29. 3. 2023 ... is redefining immuno-oncology. $GNLX is a late clinical-stage biotechnology company focused on improving the lives of patients affected by ...Genelux Corp Follow Share $11.87 After Hours: $11.87 (0.00%) 0.00 Closed: Nov 17, 4:02:25 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to SHENGFENG DEVELOPMENT Ltd $11.23 SFWL1.91%...WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...A look at the shareholders of Genelux Corporation (NASDAQ:GNLX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 57% ownership.Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.
On September 18, 2023, John Thomas, a director at Genelux Corp ( NASDAQ:GNLX ), sold 6,667 shares of the company. This move comes amidst a year where the insider has sold a total of 6,667 shares ...
GNLX. --Genelux Corporation, a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share ...52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.12. 6. 2023 ... ... (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common ...Genelux Stock Price, News & Analysis (NASDAQ:GNLX) $11.90 +0.20 (+1.71%) (As of 11/30/2023 ET) Compare Today's Range $11.46 $12.00 50-Day Range …WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...Web17. 4. 2023 ... Genelux President, CEO & Chairman Thomas Zindrick shares how being #NasdaqListed helps $GNLX reach its goals in improving the lives of the ...WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...WebThe latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ...
Mar 23, 2023 · WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ... WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...Genelux Corporation (GNLX) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » GNLX Genelux …GNLX - Genelux Corp - Stock screener for investors and traders, financial ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).Instagram:https://instagram. best trading coursebest stocks to buy under dollar5janus contrarian fund dforward dividend and yield 52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.Web collectibles insurance services reviewtesla and bmw car On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp ( NASDAQ:GNLX ). This move comes amidst a year where the insider has sold a total of 89,893 shares and purchased ...Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. arthur j gallgher Dec 1, 2023 · If you're new to stock investing, here's how to buy Genelux stock. What is the 52 week high and low for Genelux (NASDAQ: GNLX)? (NASDAQ: GNLX) Genelux's 52-week high was $40.98, and its 52-week low was $5.35. It is currently -57.93% from its 52-week high and 222.24% from its 52-week low. Genelux (NASDAQ:GNLX) PT Lowered to $30.00 americanbankingnews.com - November 25 at 3:58 AM: Genelux VP Sold $191K In Company Stock benzinga.com - November 23 at 12:58 PM: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25% finance.yahoo.com - November 17 at 8:49 AMSep 8, 2023 · In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.